Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 125387, 9 pages
http://dx.doi.org/10.1155/2008/125387
Review Article

PPAR 𝜹 Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities

Department of Cardiovascular and Metabolic Diseases, Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA

Received 30 June 2008; Accepted 3 September 2008

Academic Editor: Francine M. Gregoire

Copyright © 2008 Mylène Perreault et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Hossain, B. Kawar, and M. El Nahas, “Obesity and diabetes in the developing world—a growing challenge,” The New England Journal of Medicine, vol. 356, no. 3, pp. 213–215, 2007. View at Publisher · View at Google Scholar · View at PubMed
  2. S. Abu-Abid, A. Szold, and J. Klausner, “Obesity and cancer,” Journal of Medicine, vol. 33, no. 1–4, pp. 73–86, 2002. View at Google Scholar
  3. L. Garfinkel, “Overweight and cancer,” Annals of Internal Medicine, vol. 103, no. 6, part 2, pp. 1034–1036, 1985. View at Google Scholar
  4. R. F. Gillum, “The association of body fat distribution with hypertension, hypertensive heart disease, coronary heart disease, diabetes and cardiovascular risk factors in men and women aged 18–79 years,” Journal of Chronic Diseases, vol. 40, no. 5, pp. 421–428, 1987. View at Publisher · View at Google Scholar
  5. J. R. Pender and W. J. Pories, “Epidemiology of obesity in the United States,” Gastroenterology Clinics of North America, vol. 34, no. 1, pp. 1–7, 2005. View at Publisher · View at Google Scholar · View at PubMed
  6. N. M. Petry, D. Barry, R. H. Pietrzak, and J. A. Wagner, “Overweight and obesity are associated with psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions,” Psychosomatic Medicine, vol. 70, no. 3, pp. 288–297, 2008. View at Publisher · View at Google Scholar · View at PubMed
  7. L. Fontana, J. C. Eagon, M. E. Trujillo, P. E. Scherer, and S. Klein, “Visceral fat adipokine secretion is associated with systemic inflammation in obese humans,” Diabetes, vol. 56, no. 4, pp. 1010–1013, 2007. View at Publisher · View at Google Scholar · View at PubMed
  8. C. J. Lyon, R. E. Law, and W. A. Hsueh, “Minireview: adiposity, inflammation, and atherogenesis,” Endocrinology, vol. 144, no. 6, pp. 2195–2200, 2003. View at Publisher · View at Google Scholar
  9. A. Thörne, F. Lönnqvist, J. Apelman, G. Hellers, and P. Arner, “A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding,” International Journal of Obesity, vol. 26, no. 2, pp. 193–199, 2002. View at Publisher · View at Google Scholar
  10. S. Klein, L. Fontana, L. Young et al., “Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease,” The New England Journal of Medicine, vol. 350, no. 25, pp. 2549–2557, 2004. View at Publisher · View at Google Scholar · View at PubMed
  11. D. Rucker, R. Padwal, S. K. Li, C. Curioni, and D. C. W. Lau, “Long term pharmacotherapy for obesity and overweight: updated meta-analysis,” British Medical Journal, vol. 335, no. 7631, pp. 1194–1199, 2007. View at Publisher · View at Google Scholar · View at PubMed
  12. C. A. Miller and C. J. Rosen, “Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee meeting on June 13, 2007,” Food and Drug Administration, Center for Drug Evaluation and Research, 2007, http://www.fda.gov/ohrms/dockets/ac/07/minutes/2007-4306m1-final.pdf.
  13. J. B. Buse, D. C. Klonoff, L. L. Nielsen et al., “Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials,” Clinical Therapeutics, vol. 29, no. 1, pp. 139–153, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. C. W. Chia and J. M. Egan, “Special features: incretin-based therapies in type 2 diabetes mellitus,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 10, pp. 3703–3716, 2008. View at Publisher · View at Google Scholar · View at PubMed
  15. FDA, “Information for Healthcare Professionals,” 2008, http://www.fda.gov/cder/drug/infopage/exenatide/default.htm.
  16. Y.-X. Wang, C.-H. Lee, S. Tiep et al., “Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. View at Publisher · View at Google Scholar
  17. D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear receptor superfamily: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995. View at Publisher · View at Google Scholar
  18. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar
  19. T. Heinzel, R. M. Lavinsky, T.-M. Mullen et al., “A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression,” Nature, vol. 387, no. 6628, pp. 43–48, 1997. View at Publisher · View at Google Scholar · View at PubMed
  20. V. Cavailles, S. Dauvois, F. L'Horset et al., “Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor,” The EMBO Journal, vol. 14, no. 15, pp. 3741–3751, 1995. View at Google Scholar
  21. J. D. Chen, K. Umesono, and R. M. Evans, “SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 15, pp. 7567–7571, 1996. View at Publisher · View at Google Scholar
  22. S. A. Onate, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley, “Sequence and characterization of a coactivator for the steroid hormone receptor superfamily,” Science, vol. 270, no. 5240, pp. 1354–1357, 1995. View at Publisher · View at Google Scholar
  23. L. Gelman, G. Zhou, L. Fajas, E. Raspé, J.-C. Fruchart, and J. Auwerx, “p300 interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner, respectively,” The Journal of Biological Chemistry, vol. 274, no. 12, pp. 7681–7688, 1999. View at Publisher · View at Google Scholar
  24. C. A. Heinlein, H.-J. Ting, S. Yeh, and C. Chang, “Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor γ,” The Journal of Biological Chemistry, vol. 274, no. 23, pp. 16147–16152, 1999. View at Publisher · View at Google Scholar
  25. J. Wilding, “Thiazolidinediones, insulin resistance and obesity: finding a balance,” International Journal of Clinical Practice, vol. 60, no. 10, pp. 1272–1280, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. C. J. de Souza, M. Eckhardt, K. Gagen et al., “Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance,” Diabetes, vol. 50, no. 8, pp. 1863–1871, 2001. View at Publisher · View at Google Scholar
  27. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar
  28. T. Yamauchi, J. Kamon, H. Waki et al., “The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance,” The Journal of Biological Chemistry, vol. 276, no. 44, pp. 41245–41254, 2001. View at Publisher · View at Google Scholar · View at PubMed
  29. I. E. Kelly, T. S. Han, K. Walsh, and M. E. J. Lean, “Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes,” Diabetes Care, vol. 22, no. 2, pp. 288–293, 1999. View at Publisher · View at Google Scholar
  30. Y. Miyazaki, A. Mahankali, M. Matsuda et al., “Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 6, pp. 2784–2791, 2002. View at Publisher · View at Google Scholar
  31. A. L. Hevener, J. M. Olefsky, D. Reichart et al., “Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones,” Journal of Clinical Investigation, vol. 117, no. 6, pp. 1658–1669, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. A. Hammarstedt, V. R. Sopasakis, S. Gogg, P.-A. Jansson, and U. Smith, “Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects,” Diabetologia, vol. 48, no. 1, pp. 96–104, 2005. View at Publisher · View at Google Scholar · View at PubMed
  33. G. Jiang, Q. Dallas-Yang, Z. Li et al., “Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARγ agonists,” Diabetes, vol. 51, no. 8, pp. 2412–2419, 2002. View at Publisher · View at Google Scholar
  34. N. Kubota, Y. Terauchi, T. Kubota et al., “Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways,” The Journal of Biological Chemistry, vol. 281, no. 13, pp. 8748–8755, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. J.-C. Fruchart, “Novel peroxisome proliferator activated receptor-α agonists,” American Journal of Cardiology, vol. 100, no. 11, supplement 1, pp. S41–S46, 2007. View at Publisher · View at Google Scholar · View at PubMed
  36. C. S. Elangbam, R. D. Tyler, and R. M. Lightfoot, “Peroxisome proliferator-activated receptors in atherosclerosis and inflammation—an update,” Toxicologic Pathology, vol. 29, no. 2, pp. 224–231, 2001. View at Publisher · View at Google Scholar
  37. G. A. Francis, E. Fayard, F. Picard, and J. Auwerx, “Nuclear receptors and the control of metabolism,” Annual Review of Physiology, vol. 65, pp. 261–311, 2003. View at Publisher · View at Google Scholar · View at PubMed
  38. J. Fu, S. Gaetani, F. Oveisi et al., “Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α,” Nature, vol. 425, no. 6953, pp. 90–93, 2003. View at Publisher · View at Google Scholar · View at PubMed
  39. M. C. Carmona, K. Louche, M. Nibbelink et al., “Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice,” International Journal of Obesity, vol. 29, no. 7, pp. 864–871, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. F. Rodríguez de Fonseca, M. Navarro, R. Gómez et al., “An anorexic lipid mediator regulated by feeding,” Nature, vol. 414, no. 6860, pp. 209–212, 2001. View at Publisher · View at Google Scholar · View at PubMed
  41. T. Inagaki, P. Dutchak, G. Zhao et al., “Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21,” Cell Metabolism, vol. 5, no. 6, pp. 415–425, 2007. View at Publisher · View at Google Scholar · View at PubMed
  42. M. K. Badman, P. Pissios, A. R. Kennedy, G. Koukos, J. S. Flier, and E. Maratos-Flier, “Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states,” Cell Metabolism, vol. 5, no. 6, pp. 426–437, 2007. View at Publisher · View at Google Scholar · View at PubMed
  43. A. Kharitonenkov, V. J. Wroblewski, A. Koester et al., “The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21,” Endocrinology, vol. 148, no. 2, pp. 774–781, 2007. View at Publisher · View at Google Scholar · View at PubMed
  44. E. Scharrer, “Control of food intake by fatty acid oxidation and ketogenesis,” Nutrition, vol. 15, no. 9, pp. 704–714, 1999. View at Publisher · View at Google Scholar
  45. M. Sun, R. J. Martin, and G. L. Edwards, “ICV β-hydroxybutyrate: effects on food intake, body composition, and body weight in rats,” Physiology and Behavior, vol. 61, no. 3, pp. 433–436, 1997. View at Publisher · View at Google Scholar
  46. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at PubMed
  47. D. Arsenijevic, F. De Bilbao, J. Plamondon et al., “Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor β-deficient mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 26, no. 3, pp. 433–445, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. T. Tanaka, J. Yamamoto, S. Iwasaki et al., “Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924–15929, 2003. View at Publisher · View at Google Scholar · View at PubMed
  49. C. Fürnsinn, T. M. Willson, and B. Brunmair, “Peroxisome proliferator-activated receptor-δ, a regulator of oxidative capacity, fuel switching and cholesterol transport,” Diabetologia, vol. 50, no. 1, pp. 8–17, 2007. View at Publisher · View at Google Scholar · View at PubMed
  50. D. L. Sprecher, C. Massien, G. Pearce et al., “Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 359–365, 2007. View at Publisher · View at Google Scholar · View at PubMed
  51. K. Kannisto, A. Chibalin, B. Glinghammar, J. R. Zierath, A. Hamsten, and E. Ehrenborg, “Differential expression of peroxisomal proliferator activated receptors α and δ in skeletal muscle in response to changes in diet and exercise,” International Journal of Molecular Medicine, vol. 17, no. 1, pp. 45–52, 2006. View at Google Scholar
  52. S. Luquet, J. Lopez-Soriano, D. Holst et al., “Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability,” The FASEB Journal, vol. 17, no. 15, pp. 2299–2301, 2003. View at Publisher · View at Google Scholar · View at PubMed
  53. D. J. Mahoney, G. Parise, S. Melov, A. Safdar, and M. A. Tarnopolsky, “Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise,” The FASEB Journal, vol. 19, no. 11, pp. 1498–1500, 2005. View at Publisher · View at Google Scholar · View at PubMed
  54. M. J. Watt, R. J. Southgate, A. G. Holmes, and M. A. Febbraio, “Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) α and δ and PPAR coactivator 1α in human skeletal muscle, but not lipid regulatory genes,” Journal of Molecular Endocrinology, vol. 33, no. 2, pp. 533–544, 2004. View at Publisher · View at Google Scholar · View at PubMed
  55. Y.-X. Wang, C.-L. Zhang, R. T. Yu et al., “Regulation of muscle fiber type and running endurance by PPARδ,” PLoS Biology, vol. 2, no. 10, p. e294, 2004. View at Publisher · View at Google Scholar · View at PubMed
  56. C.-H. Lee, P. Olson, A. Hevener et al., “PPARδ regulates glucose metabolism and insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3444–3449, 2006. View at Publisher · View at Google Scholar · View at PubMed
  57. K. Kang, S. M. Reilly, V. Karabacak et al., “Adipocyte-derived Th2 cytokines and myeloid PPARδ regulate macrophage polarization and insulin sensitivity,” Cell Metabolism, vol. 7, no. 6, pp. 485–495, 2008. View at Publisher · View at Google Scholar · View at PubMed
  58. J. I. Odegaard, R. R. Ricardo-Gonzalez, A. R. Eagle et al., “Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance,” Cell Metabolism, vol. 7, no. 6, pp. 496–507, 2008. View at Publisher · View at Google Scholar · View at PubMed
  59. J. D. Tugwood, P. R. Holden, N. H. James, R. A. Prince, and R. A. Roberts, “A peroxisome proliferator-activated receptor-alpha (PPARα) cDNA cloned from guinea-pig liver encodes a protein wit h similar properties to the mouse PPARα: implications for species differences in responses to peroxisome proliferators,” Archives of Toxicology, vol. 72, no. 3, pp. 169–177, 1998. View at Publisher · View at Google Scholar
  60. T. L. Graham, C. Mookherjee, K. E. Suckling, C. N. A. Palmer, and L. Patel, “The PPARδ agonist GW0742X reduces atherosclerosis in LDLR/ mice,” Atherosclerosis, vol. 181, no. 1, pp. 29–37, 2005. View at Publisher · View at Google Scholar · View at PubMed
  61. A. C. Li, C. J. Binder, A. Gutierrez et al., “Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ,” Journal of Clinical Investigation, vol. 114, no. 11, pp. 1564–1576, 2004. View at Publisher · View at Google Scholar · View at PubMed
  62. Y. Takata, J. Liu, F. Yin et al., “PPARδ-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 11, pp. 4277–4282, 2008. View at Publisher · View at Google Scholar · View at PubMed
  63. W. R. Oliver, Jr., J. L. Shenk, M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001. View at Publisher · View at Google Scholar · View at PubMed
  64. N. Vu-Dac, S. Chopin-Delannoy, P. Gervois et al., “The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates,” The Journal of Biological Chemistry, vol. 273, no. 40, pp. 25713–25720, 1998. View at Publisher · View at Google Scholar
  65. B. Staels and J. Auwerx, “Regulation of apo A-I gene expression by fibrates,” Atherosclerosis, vol. 137, pp. S19–S23, 1998. View at Publisher · View at Google Scholar
  66. J. Rudolph, C. Libing, D. Majumdar et al., “Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR α/γ/δ pan agonists: synthesis, structure-activity relationship, and in vivo efficacy,” Journal of Medicinal Chemistry, vol. 50, no. 5, pp. 984–1000, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. J. Berger, M. D. Leibowitz, T. W. Doebber et al., “Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects,” The Journal of Biological Chemistry, vol. 274, no. 10, pp. 6718–6725, 1999. View at Publisher · View at Google Scholar
  68. T. M. Willson, J. E. Cobb, D. J. Cowan et al., “The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 665–668, 1996. View at Publisher · View at Google Scholar · View at PubMed
  69. M. Perreault et al., “PPAR pan agonists: novel approaches to treating type 2 diabetes and metabolic syndrome,” Obesity, vol. 14, p. A62, 2006. View at Google Scholar
  70. M. Perreault et al., “PPAR pan agonists induce body weight loss in DIO mice,” Obesity, vol. 14, p. A62, 2006. View at Google Scholar
  71. S. C. Cheol, D. B. Savage, L. Abu-Elheiga et al., “Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 42, pp. 16480–16485, 2007. View at Publisher · View at Google Scholar · View at PubMed
  72. L. Abu-Elheiga, M. M. Matzuk, K. A. H. Abo-Hashema, and S. J. Wakil, “Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-COA carboxylase 2,” Science, vol. 291, no. 5513, pp. 2613–2616, 2001. View at Publisher · View at Google Scholar · View at PubMed
  73. B. N. Finck, C. Bernal-Mizrachi, D. H. Han et al., “A potential link between muscle peroxisome proliferator-activated receptor-α signaling and obesity-related diabetes,” Cell Metabolism, vol. 1, no. 2, pp. 133–144, 2005. View at Publisher · View at Google Scholar · View at PubMed
  74. F. Djouadi, F. Aubey, D. Schlemmer, and J. Bastin, “Peroxisome proliferator activated receptor δ (PPARδ) agonist but not PPARα corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 3, pp. 1791–1797, 2005. View at Publisher · View at Google Scholar · View at PubMed
  75. I. Pruimboom-Brees, M. Haghpassand, L. Royer et al., “A critical role for peroxisomal proliferator-activated receptor-α nuclear receptors in the development of cardiomyocyte degeneration and necrosis,” American Journal of Pathology, vol. 169, no. 3, pp. 750–760, 2006. View at Publisher · View at Google Scholar
  76. B. N. Finck, X. Han, M. Courtois et al., “A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 1226–1231, 2003. View at Publisher · View at Google Scholar · View at PubMed
  77. E. M. Burkart, N. Sambandam, X. Han et al., “Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart,” Journal of Clinical Investigation, vol. 117, no. 12, pp. 3930–3939, 2007. View at Publisher · View at Google Scholar · View at PubMed
  78. M. Pesant, S. Sueur, P. Dutartre et al., “Peroxisome proliferator-activated receptor δ (PPARδ) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis,” Cardiovascular Research, vol. 69, no. 2, pp. 440–449, 2006. View at Publisher · View at Google Scholar · View at PubMed
  79. T. R. Koves, J. R. Ussher, R. C. Noland et al., “Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance,” Cell Metabolism, vol. 7, no. 1, pp. 45–56, 2008. View at Publisher · View at Google Scholar · View at PubMed
  80. H. Yki-Järvinen, “Thiazolidinediones,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, 2004. View at Publisher · View at Google Scholar · View at PubMed
  81. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Publisher · View at Google Scholar · View at PubMed
  82. GlaxoSmithKline, “Advisory Committee Briefing Document, Cardiovascular Safety of Rosiglitazone, Endocrinologic and Metabolic Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, Meeting on July 30, 2007”.
  83. G. A. Diamond, L. Bax, and S. Kaul, “Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death,” Annals of Internal Medicine, vol. 147, no. 8, pp. 578–581, 2007. View at Google Scholar
  84. A. T. McAfee, C. Koro, J. Landon, N. Ziyadeh, and A. M. Walker, “Coronary heart disease outcomes in patients receiving antidiabetic agents,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 7, pp. 711–725, 2007. View at Publisher · View at Google Scholar · View at PubMed
  85. A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen, “Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials,” Journal of the American Medical Association, vol. 298, no. 10, pp. 1180–1188, 2007. View at Publisher · View at Google Scholar · View at PubMed
  86. R. B. Goldberg, D. M. Kendall, M. A. Deeg et al., “A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia,” Diabetes Care, vol. 28, no. 7, pp. 1547–1554, 2005. View at Publisher · View at Google Scholar
  87. S. Qin, T. Liu, V. S. Kamanna, and M. L. Kashyap, “Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-α,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 11, pp. 2428–2434, 2007. View at Publisher · View at Google Scholar · View at PubMed
  88. J. Sakamoto, H. Kimura, S. Moriyama et al., “Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone,” Biochemical and Biophysical Research Communications, vol. 278, no. 3, pp. 704–711, 2000. View at Publisher · View at Google Scholar · View at PubMed
  89. P. D. Home, S. J. Pocock, H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis,” The New England Journal of Medicine, vol. 357, no. 1, pp. 28–38, 2007. View at Publisher · View at Google Scholar · View at PubMed
  90. J. M. Drazen, S. Morrissey, and G. D. Curfman, “Rosiglitazone—continued uncertainty about safety,” The New England Journal of Medicine, vol. 357, no. 1, pp. 63–64, 2007. View at Publisher · View at Google Scholar · View at PubMed
  91. D. M. Nathan, “Rosiglitazone and cardiotoxicity—weighing the evidence,” The New England Journal of Medicine, vol. 357, no. 1, pp. 64–66, 2007. View at Publisher · View at Google Scholar · View at PubMed
  92. B. M. Psaty and C. D. Furberg, “The record on rosiglitazone and the risk of myocardial infarction,” The New England Journal of Medicine, vol. 357, no. 1, pp. 67–69, 2007. View at Publisher · View at Google Scholar · View at PubMed
  93. FDA, “Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention,” Draft Guidance, FDA, 2008.
  94. T. Aoki, “Current status of carcinogenicity assessment of peroxisome proliferator-activated receptor agonists by the US FDA and a mode-of-action approach to the carcinogenic potential,” Journal of Toxicologic Pathology, vol. 20, no. 4, pp. 197–202, 2008. View at Publisher · View at Google Scholar
  95. A. V. Schwartz and D. E. Sellmeyer, “Thiazolidinediones: new evidence of bone loss,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 4, pp. 1232–1234, 2007. View at Publisher · View at Google Scholar · View at PubMed
  96. S. E. Kahn, B. Zinman, J. M. Lachin et al., “Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT),” Diabetes Care, vol. 31, no. 5, pp. 845–851, 2008. View at Publisher · View at Google Scholar · View at PubMed
  97. C. Meier, M. E. Kraenzlin, M. Bodmer, S. S. Jick, H. Jick, and C. R. Meier, “Use of thiazolidinediones and fracture risk,” Archives of Internal Medicine, vol. 168, no. 8, pp. 820–825, 2008. View at Publisher · View at Google Scholar · View at PubMed
  98. O. P. Lazarenko, S. O. Rzonca, W. R. Hogue, F. L. Swain, L. J. Suva, and B. Lecka-Czernik, “Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone,” Endocrinology, vol. 148, no. 6, pp. 2669–2680, 2007. View at Publisher · View at Google Scholar · View at PubMed
  99. A. A. Ali, R. S. Weinstein, S. A. Stewart, A. M. Parfitt, S. C. Manolagas, and R. L. Jilka, “Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation,” Endocrinology, vol. 146, no. 3, pp. 1226–1235, 2005. View at Publisher · View at Google Scholar · View at PubMed
  100. Y. Wan, L.-W. Chong, and R. M. Evans, “PPAR-γ regulates osteoclastogenesis in mice,” Nature Medicine, vol. 13, no. 12, pp. 1496–1503, 2007. View at Publisher · View at Google Scholar · View at PubMed
  101. C. Giaginis, A. Tsantili-Kakoulidou, and S. Theocharis, “Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism,” Fundamental and Clinical Pharmacology, vol. 21, no. 3, pp. 231–244, 2007. View at Publisher · View at Google Scholar · View at PubMed
  102. S. M. Jackson and L. L. Demer, “Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts,” FEBS Letters, vol. 471, no. 1, pp. 119–124, 2000. View at Publisher · View at Google Scholar
  103. H. Mano, C. Kimura, Y. Fujisawa et al., “Cloning and function of rabbit peroxisome proliferator-activated receptor δ/β in mature osteoclasts,” The Journal of Biological Chemistry, vol. 275, no. 11, pp. 8126–8132, 2000. View at Publisher · View at Google Scholar
  104. A. C. Maurin, P. M. Chavassieux, and P. J. Meunier, “Expression of PPARγ and β/δ in human primary osteoblastic cells: influence of polyunsaturated fatty acids,” Calcified Tissue International, vol. 76, no. 5, pp. 385–392, 2005. View at Publisher · View at Google Scholar · View at PubMed